share_log

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target

JMP Securities重申藍圖藥物的市場表現跑贏大盤,維持114美元的目標股價
Moomoo 24/7 ·  04/10 11:02

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $114 price target.

JMP Securities分析師雷尼·本傑明重申藍圖藥業(納斯達克股票代碼:BPMC)的市場表現優於大盤,並維持114美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論